TINAVI(688277)

Search documents
存量32家未盈利企业进入科创成长层(附名单)





财联社· 2025-07-13 07:59
Group 1 - The Shanghai Stock Exchange has released the "Self-Regulatory Supervision Guidelines for Companies Listed on the Sci-Tech Innovation Board No. 5 - Sci-Tech Growth Tier" [1] - The reform does not impose additional listing thresholds for unprofitable companies entering the Sci-Tech Growth Tier, allowing 32 existing unprofitable companies to enter immediately upon the guideline's implementation [1] - Newly registered unprofitable companies will enter the Sci-Tech Growth Tier from the date of their listing [1] Group 2 - Investors participating in the subscription and trading of newly registered stocks in the Sci-Tech Growth Tier must sign a "Risk Disclosure Statement for the Sci-Tech Growth Tier" [2] - The 32 existing companies that have not yet removed the "U" designation include: Zejing Pharmaceutical, Junshi Biosciences, Frontier Biotech, Qingyun Technology, Hehui Optoelectronics, Jingjin Electric, BeiGene, Dize Pharmaceutical, Maiwei Biotech, Aojie Technology, Yuhong Pharmaceutical, Shouyao Holdings, Haichuang Pharmaceutical, CloudWalk Technology, Yifang Biotech, Obsidian Optics, Mengke Pharmaceutical, Nuo Cheng Jianhua, Xinke Mobile, Xinghuan Technology, Yutai Micro, Yuntian Lifa, Tianzhihang, Qi Anxin, Hanwujin, Yihua Tong, Aifute, Huizhiwei, Xinlian Integrated, Zhixiang Jintai, Shengke Communication, and Zhongjuxin [2]
天智航: 关于持股5%以上股东权益变动触及1%刻度的提示性公告
Zheng Quan Zhi Xing· 2025-07-04 16:34
Core Viewpoint - The announcement details a change in shareholding for Beijing Tianzhihang Medical Technology Co., Ltd., where a significant shareholder has reduced their stake from 9.66% to 9.00% through a share reduction of 2,989,572 shares, representing 0.66% of the total share capital [1][2]. Group 1: Shareholding Changes - The advanced manufacturing industry investment fund and its action partner, the Beijing-Tianjin-Hebei industrial collaborative development investment fund, have reduced their combined shareholding from 9.66% to 9.00% [1][2]. - The reduction was executed through centralized bidding, and the reduction plan is not yet fully implemented [2][4]. - The shareholding change does not trigger mandatory tender offer obligations [1][2]. Group 2: Shareholder Information - The advanced manufacturing industry investment fund and the Beijing-Tianjin-Hebei industrial collaborative development investment fund are identified as the significant shareholders and action partners [1][3]. - The announcement confirms that the information provided by the shareholders is accurate and complete, with no misleading statements or omissions [1].
天智航(688277) - 关于持股5%以上股东权益变动触及1%刻度的提示性公告
2025-07-04 13:33
证券代码:688277 证券简称:天智航 公告编号:2025-029 北京天智航医疗科技股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的提示性公告 先进制造产业投资基金(有限合伙)及其一致行动人京津冀产业协同发 展投资基金(有限合伙)保证向本公司提供的信息真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息 一致。 重要内容提示: 2.信息披露义务人信息 | 信息披露义务人名称 | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | | | □ 控股股东/实控人 | | | 先进制造产业投资基 | □ 控股股东/实控人的 | ☑ 91310000342453915W | | 金(有限合伙) | 一致行动人 | 不适用 □ | | | 其他直接持股股东 ☑ | | | | □ 控股股东/实控人 | | | | | --- | --- | --- | --- | --- | | 京津冀产业协同发展 | □ | 控股股东/实控人的 | ☑ | 91130600MA0939HK85 | | 投资基金(有限合伙) | ...
AI与机器人盘前速递丨具身大模型机器人领域最大单笔融资出现,中国银行业大模型应用走在前列
Xin Lang Cai Jing· 2025-06-24 01:14
Market Overview - On June 23, 2025, the Sci-Tech Innovation Artificial Intelligence ETF (Hua Xia, 589010) closed down 0.72%, with leading declines from Hengxuan Technology down 5.46%, Lanke Technology down 4.36%, and Stone Technology down 3.62% [1] - The Robotics ETF (562500) closed up 0.50%, with East杰智能 leading gains at 10.47%, Tianzhihang up 7.27%, and Kuaike Intelligent up 3.04% [1] - The trading volume for the day was 359 million yuan, making it the most active ETF in its category, indicating good liquidity [1] Key Developments - Huawei and Softcom Power are collaborating to develop humanoid robots for manufacturing scenarios, focusing on general humanoid applications and 3C manufacturing [2] - KPMG's 2025 China Banking Industry Survey Report indicates that the banking sector is leading in the application of large models, with significant efficiency improvements and innovations across various banking operations [2] - Galaxy General announced the completion of a new financing round of 1.1 billion yuan, marking the largest single financing in the field of embodied large model robots, with total financing exceeding 2.4 billion yuan over two years [2] Institutional Insights - China Galaxy Securities states that A-shares are currently at a historical average valuation, relatively low compared to mature overseas markets, suggesting high investment value [3] - The report anticipates a stable upward trend for A-shares in the second half of 2025, driven by policy support and capital inflows, while cautioning about external uncertainties and domestic economic recovery [3] - The focus on technology innovation is highlighted as a core driver for A-share supply-side reform, with recommendations to pay attention to AI computing, AI applications, embodied intelligence, and innovative pharmaceuticals [3] ETF Highlights - The Robotics ETF (562500) is noted as the only ETF in the market with over 10 billion yuan in scale, offering the best liquidity and comprehensive coverage of the Chinese robotics industry [4] - The Sci-Tech Innovation Artificial Intelligence ETF (Hua Xia, 589010) is described as the "brain" of robotics, capturing the "singularity moment" in the AI industry with a 20% fluctuation range and small to mid-cap elasticity [4]
天智航:以原研创新为帆 破浪骨科手术机器人新蓝海
Zheng Quan Ri Bao· 2025-06-22 17:11
Core Viewpoint - The demand for orthopedic surgeries is increasing due to aging populations and younger patients with orthopedic diseases, driving the need for precision, minimally invasive, and intelligent surgical solutions, which in turn fosters the growth of orthopedic surgical robots [2][7]. Group 1: Company Overview - Beijing Tianzhihang Medical Technology Co., Ltd. (Tianzhihang) is transforming the global orthopedic surgical robot market with its core product, the Tianji orthopedic surgical robot, achieving sub-millimeter precision and completing over 110,000 surgeries across more than 200 hospitals in China [2][4]. - The company adheres to the principle of "original research and innovation," with R&D investment of 117 million yuan in 2024, accounting for 65.34% of its revenue, and employs 123 R&D personnel, making up 40.07% of its workforce [3][4]. Group 2: Product Development - Tianzhihang has introduced multiple generations of its surgical robots, with the Tianji® 1.0 launched in 2016 and the Tianji® 2.0 in 2021, enhancing usability and humanization [4]. - The company has achieved full coverage in three major orthopedic fields: spine, trauma, and joints, with a total of 596 patent applications, including 232 invention patents, and 401 patents granted [4][8]. Group 3: Technological Advancements - Tianzhihang has pioneered remote orthopedic surgeries in China since 2006 and has conducted over 1,000 remote surgeries using 5G technology, showcasing the potential of "5G + robotics" in healthcare [6][8]. - The company emphasizes the importance of orthopedic surgical robots in addressing uneven distribution of medical resources and enhancing capabilities in grassroots medical institutions [7]. Group 4: Market Position and Growth - The Chinese surgical robot market is projected to reach approximately 9.59 billion yuan in 2024, with a compound annual growth rate of 34.5% over the past five years, and is expected to grow to 11.03 billion yuan by 2025 [8]. - Tianzhihang's revenue structure has evolved, with more than 50% of its income now coming from consumables and technical services, compared to nearly 100% from hardware four years ago [8]. Group 5: International Expansion - The company aims to expand internationally, with its surgical navigation systems receiving EU CE certification, facilitating its entry into overseas markets [9]. - Tianzhihang plans to develop differentiated market strategies based on the characteristics of various international markets, positioning itself as a significant player in the global orthopedic surgical robot arena [9].
天智航: 关于召开2024年度暨2025年第一季度业绩说明会的公告
Zheng Quan Zhi Xing· 2025-06-19 11:04
Core Viewpoint - Beijing Tinavi Medical Technology Co., Ltd. will hold a performance briefing for the fiscal year 2024 and the first quarter of 2025 on June 27, 2025, to discuss operational results and financial status with investors [1][2]. Group 1: Meeting Details - The performance briefing will take place on June 27, 2025, from 10:00 to 11:00 AM [4]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center, accessible via the website: https://roadshow.sseinfo.com/ [4]. - The format of the meeting will be an online interactive session [4]. Group 2: Participation Information - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date [2]. - Questions can be submitted by investors from June 20 to June 26, 2025, through the "Question Pre-Collection" section on the website or via the company's email [2][4]. - The company will address commonly asked questions during the briefing [2][4]. Group 3: Attendees - The attendees of the briefing will include the company's General Manager, Mr. Xu Jin, Independent Director, Ms. Zhang Ruijun, Chief Financial Officer, Ms. Qi Min, and Secretary of the Board, Mr. Huang Junhui [1].
天智航(688277) - 关于召开2024年度暨2025年第一季度业绩说明会的公告
2025-06-19 10:30
关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 证券代码:688277 证券简称:天智航 公告编号:2025-028 北京天智航医疗科技股份有限公司 北京天智航医疗科技股份有限公司(以下简称"公司")已于 2025 年 4 月 29 日发布公司 2024 年年度报告和 2025 年第一季度报告,为便于广大投资者更 全面深入地了解公司 2024 年度、2025 年第一季度经营成果、财务状况,公司计 划于 2025 年 6 月 27 日上午 10:00-11:00 举行 2024 年度暨 2025 年第一季度业绩 说明会,就投资者关心的问题进行交流。 三、参加人员 参加本次业绩说明会的人员有:公司总经理徐进先生、独立董事张瑞君女士、 财务总监齐敏女士、董事会秘书黄军辉先生(如有特殊情况,参会人员可能进行 调整)。 四、投资者参加方式 一、说明会类型 本次投资者说明会以网络互动形式召开,公司将针对 2024 年度及 2025 年第 一季度的经营成果 ...
北京天智航医疗科技股份有限公司 关于变更持续督导保荐代表人的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-06-13 23:42
Group 1 - The company has announced a change in the continuous supervision representative for its initial public offering (IPO) project due to the work relocation of the previous representative, Lu Danjun [1][2] - CITIC Securities, as the sponsor and continuous supervision institution, will continue to fulfill its supervisory responsibilities until the raised funds are fully utilized, which is expected to be by December 31, 2023 [1][2] - The company expresses gratitude to Lu Danjun for his contributions during the IPO and continuous supervision period [3] Group 2 - Shao Luwei has been appointed as the new continuous supervision representative, taking over from Lu Danjun [2] - The current continuous supervision representatives for the IPO project are Sun Dong and Shao Luwei [2] - Shao Luwei holds a master's degree and has participated in various IPO projects, including those of Yunzhongma and Jinchun Co., among others [4]
天智航(688277) - 关于变更持续督导保荐代表人的公告
2025-06-13 09:45
特此公告。 北京天智航医疗科技股份有限公司董事会 2025 年 6 月 14 日 证券代码:688277 证券简称:天智航 公告编号:2025-027 中信建投作为公司首发上市项目的保荐机构和持续督导机构,法定持续督导 期限至 2023 年 12 月 31 日止,因公司本次发行募集资金尚未使用完毕,中信建 投将就未使用完毕的募集资金使用情况继续履行持续督导责任,直至募集资金使 用完毕。 为保证公司持续督导工作的有序进行,中信建投委派邵路伟先生(简历详见 附件)接替陆丹君先生担任公司持续督导保荐代表人,继续履行相关职责。本次 保荐代表人变更后,公司首发上市项目持续督导期保荐代表人为孙栋先生和邵路 伟先生。 公司董事会对陆丹君先生在公司首发上市项目保荐发行及持续督导期间所 做的贡献表示衷心的感谢! 北京天智航医疗科技股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 北京天智航医疗科技股份有限公司(以下简称"公司")于近日收到保荐机 构中信建投证券股份有限公司(以下简称"中信建投") ...
天智航-U(688277)每日收评(06-13)
He Xun Cai Jing· 2025-06-13 09:42
Group 1 - The stock of Tianzhihang (U688277) has a comprehensive score of 63.85, indicating a strong performance [1] - The main cost analysis shows the following prices: current main cost at 13.56 CNY, 5-day main cost at 13.59 CNY, 20-day main cost at 12.96 CNY, and 60-day main cost at 12.53 CNY [1] - In the past year, the stock has experienced 2 instances of hitting the upper limit and no instances of hitting the lower limit [1] Group 2 - The short-term pressure level is at 13.96 CNY, while the short-term support level is at 13.28 CNY [2] - The financial data indicates a net profit of -14,378,611.68 CNY and an operating profit of -0.18 billion CNY, with a sales gross margin of 75.12% [2][3] - The stock has seen a net outflow of main funds amounting to 493.17 million CNY, which is -3% of the total transaction amount [2][3] Group 3 - The related industry sectors, including medical devices, have shown declines of -2.21%, -2.01%, and -1.92% respectively [2][3] - The stock has a short-term and mid-term trend that is currently unclear, awaiting direction from main funds [2][3]